Detection of netrin-1 as a novel biomarker for diagnosis and chemotherapeutic monitoring of lung cancer. Issue 6 (June 2022)

• Record Type: Journal Article
• Authors: Zhao, Yuanyuan; Song, Jing; Ding, Xuejiao; Hao, Yu; Cao, Lihua
• Is Part Of: Journal of international medical research. Volume 50:Issue 6(2022)
• Publication Date: 2022-06
• Subjects: Lung cancer -- netrin-1 -- biomarker -- chemotherapy resistance -- prognosis -- cisplatin; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/03000605221105364
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: Lung cancer has high morbidity and mortality. We aimed to determine the value of netrin-1 for the diagnosis and chemotherapeutic monitoring of lung cancer. Methods: Thirty pairs of lung cancer tissues and serum were collected. Netrin-1 expression was detected by immunohistochemistry and enzyme-linked immunosorbent assay. Netrin-1 expression was downregulated in A549 cells using small interfering RNA, and the effect of netrin-1 on cisplatin-induced lung cancer cell apoptosis was determined by flow cytometry. Results: Netrin-1-positivity was significantly higher in lung cancer tissues than in paracarcinoma tissues and high expression of netrin-1 was closely related to a poor prognosis. Serum netrin-1 levels were also significantly higher in lung cancer patients than in healthy donors, and were higher in patients with lung cancer before the beginning of chemotherapy compared with after the completion of four cycles of chemotherapy. Netrin-1 knockdown increased the rate of cisplatin-induced apoptosis in A549 cells. Conclusions: Netrin-1 expression was increased in tissues and serum from lung cancer patients and decreased after chemotherapy, suggesting that it may be a potential diagnostic marker and indicator of chemosensitivity. Netrin-1 may participate in cisplatin resistance by reducing apoptosis, thus providing a new strategy for addressing chemoresistance in patients with lung cancer.